Senior investor and executive with operational and investing experience across healthcare and consumer sectors. Tabitha Letourneau Meyerer is known for leading growth-stage investing, portfolio company oversight, and strategic M&A; background includes private equity and corporate development roles, board seats, and hands-on operating leadership. Market-oriented profile: focus on scaling revenue, unit economics, and exit preparation; typically engages in Series B–C rounds and strategic carve-outs.
Senior investor and executive with operational and investing experience across healthcare and consumer sectors. Tabitha Letourneau Meyerer is known for leading growth-stage investing, portfolio company oversight, and strategic M&A; background includes private equity and corporate development roles, board seats, and hands-on operating leadership. Market-oriented profile: focus on scaling revenue, unit economics, and exit preparation; typically engages in Series B–C rounds and strategic carve-outs.
Seasoned growth-stage investor and operator focusing on healthcare and consumer businesses. Prioritizes revenue-scalable models, improving unit economics, and clear pathways to exit. Prefers Series B–C and strategic carve-outs where operational playbooks, disciplined capital allocation, and board-level engagement accelerate value creation. Underwriting emphasizes durable unit margins, repeatable go-to-market, and management quality; time horizon is medium-term (3–7 years) with active governance, milestone-based follow-on capital, and pragmatic M&A-driven liquidity as key levers.
Seasoned growth-stage investor and operator focusing on healthcare and consumer businesses. Prioritizes revenue-scalable models, improving unit economics, and clear pathways to exit. Prefers Series B–C and strategic carve-outs where operational playbooks, disciplined capital allocation, and board-level engagement accelerate value creation. Underwriting emphasizes durable unit margins, repeatable go-to-market, and management quality; time horizon is medium-term (3–7 years) with active governance, milestone-based follow-on capital, and pragmatic M&A-driven liquidity as key levers.
| Trades 1786 | Longs Won 1150/1786 64% | Profit Factor 9.16 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $1.28M |
| Average Win $175,939.34 | Best Trade (Sep 15) $48.97M | Sharpe Ratio -9.1 |
| Average Loss -$34,746.43 | Worst Trade (Mar 31) -$1.4M | Z-Score -2.2 (100%) |
| Commissions $0 | Avg. Trade Length 8m 1w 2d | Expectancy $100,913.5 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | 0.4% |
| Consecutive Losing Trades | 12,346 | 11,111 | 9,877 | 8,642 | 7,407 | 6,173 | 4,938 | 3,704 | 2,469 | 1,235 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
AAPL Apple Inc. | 450,152 | $100.4M | $140M | - | $39.59M | 39.43% | +0.524% |
ABBV AbbVie Inc. | 13,857 | $2.96M | $3.38M | - | $419,091.08 | 14.16% | 0.0 |
ABT Abbott Laboratories | 9,457 | $1.21M | $997,335.22 | - | -$215,898.41 | -17.8% | 0.0 |
ADI Analog Devices, Inc. | 5,698 | $1.5M | $2.17M | - | $662,038.01 | 43.99% | 0.0 |
ALL Allstate Corporation | 4,497 | $946,249.65 | $1.18M | - | $234,482.67 | 24.78% | 0.0 |
AMD Advanced Micro Devices, Inc. | 5,066 | $842,498.55 | $2.63M | - | $1.78M | 211.83% | 0.0 |
AMGN Amgen Inc. | 655 | $215,591.41 | $255,463.09 | - | $39,871.68 | 18.49% | 0.0 |
AMP Ameriprise Financial, Inc. | 478 | $212,423 | $264,611.25 | - | $52,188.25 | 24.57% | 0.0 |
AMT American Tower Corporation | 10,062 | $1.83M | $1.69M | - | -$141,397.8 | -7.72% | -4.097% |
AMZN Amazon.com Inc | 41,977 | $8.69M | $11.65M | - | $2.96M | 34% | 0.0 |
APH Amphenol Corporation | 63,616 | $2.13M | $2.72M | - | $598,952.17 | 28.17% | 0.0 |
ARCC Ares Capital Corporation | 11,185 | $247,859.84 | $209,830.6 | - | -$38,029.24 | -15.34% | -4.529% |
ARKK ARK Innovation ETF Fund | 3,745 | $263,236 | $287,466.2 | - | $24,230.2 | 9.2% | 0.0 |
ASML ASML Holding N.V. New York Registry Shares | 148 | $294,437 | $248,376.56 | - | -$46,060.44 | -15.64% | -1.967% |
AVGO Broadcom Inc. | 15,822 | $3.13M | $6.62M | - | $3.49M | 111.45% | 0.0 |
AXP American Express Company | 12,841 | $3.64M | $4.45M | - | $815,735.96 | 22.43% | 0.0 |
AXSM Axsome Therapeutics, Inc. | 1,477 | $179,381.93 | $321,971.24 | - | $142,589.31 | 79.49% | +2.743% |
AZO AutoZone Inc. | 272 | $973,886.84 | $823,624.17 | - | -$150,262.67 | -15.43% | 0.0 |
BAC Bank of America Corporation | 50,989 | $2.29M | $3.23M | - | $937,157.29 | 40.96% | +0.556% |
BDVL iShares Disciplined Volatility Equity Active ETF | 9,012 | $225,666.53 | $236,474.88 | - | $10,808.35 | 4.79% | -1.745% |